Reversible psychiatric adverse effects related to deep brain stimulation of the anterior thalamus in patients with refractory epilepsy by Järvenpää, Soila et al.
Epilepsy & Behavior 88 (2018) 373–379
Contents lists available at ScienceDirect
Epilepsy & Behavior
j ourna l homepage: www.e lsev ie r .com/ locate /yebehReversible psychiatric adverse effects related to deep brain stimulation of
the anterior thalamus in patients with refractory epilepsySoila Järvenpää a,b,⁎, Jukka Peltola a,b, Sirpa Rainesalo b, Esa Leinonen a,c, Kai Lehtimäki a,b, Kaija Järventausta a,c
a University of Tampere, Faculty of Medicine and Biosciences, Tampere, Finland
b Tampere University Hospital, Department of Neurosciences, Neurology and Rehabilitation, Tampere, Finland
c Tampere University Hospital, Department of Psychiatry, Tampere, FinlandAbbreviations: AED, antiepileptic drug; ANT, anterio
Alcohol Use Disorders Identiﬁcation Test; BDI, Beck De
brain stimulation; MADRS, Montgomery and Åsberg D
magnetic resonance imaging; NPI, Neuropsychiatric Inv
Checklist-90; SANTE, stimulation of the anterior nucleus
VNS, vagus nerve stimulation.
⁎ Corresponding author at: Department of Neurolog
University Hospital, PL 2000, 33521 Tampere, Finland.
E-mail addresses: soila.jarvenpaa@pshp.ﬁ (S. Järvenpä
(J. Peltola), sirpa.rainesalo@pshp.ﬁ (S. Rainesalo), esa.lein
kai.lehtimaki@pshp.ﬁ (K. Lehtimäki), kaija.jarventausta@p
https://doi.org/10.1016/j.yebeh.2018.09.006
1525-5050/© 2018 The Authors. Published by Elsevier Inca b s t r a c ta r t i c l e i n f oArticle history:
Received 2 August 2018
Revised 7 September 2018
Accepted 9 September 2018
Available online 2 October 2018Objective: Anterior nucleus of thalamus (ANT) deep brain stimulation (DBS) is becoming a more common treat-
ment for drug-resistant epilepsy. Epilepsy and depression display a bidirectional association. Anterior nucleus of
thalamus has connections to anterior cingulate cortex and orbitomedial prefrontal cortex, hence, a possible role
in emotional and executive functions, and thus, ANT DBS might exert psychiatric adverse effects. Our aimwas to
evaluate previous and current psychiatric symptoms in patients with epilepsy undergoing ANT DBS surgery and
assess the predictability of psychiatric adverse effects. Programming-related psychiatric adverse effects are also
reported.
Method: Twenty-twopatientswith ANTDBS for retractable epilepsywere examined, and a psychiatric evaluation
of depressive and other psychiatric symptoms was performed with Montgomery and Åsberg Depression Rating
Scale (MADRS), Beck Depression Inventory (BDI), and Symptom Checklist prior to surgery, concentrating on for-
mer and current psychiatric symptoms and medications. The follow-up visit was one year after surgery.
Results:At the group level, no changes onmoodwere observed during ANTDBS treatment. Two patientswith for-
mer histories of depression experienced sudden depressive symptoms related to DBS programming settings;
these were quickly alleviated after changing the stimulation parameters. In addition, two patients with no previ-
ous histories of psychosis gradually developed clear paranoid and anxiety symptoms that also relieved slowly
after changing the programming settings.
Conclusion: The majority of our ANT DBS patients did not experience psychiatric adverse effects. Certain DBS pa-
rameters might predispose to sudden depressive or slowly manifesting paranoid symptoms that are reversible
via programming changes.
© 2018 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).Keywords:
Deep brain stimulation
Anterior thalamus
Refractory epilepsy
Psychiatric symptoms
Side effects1. Introduction
One-third of patientswith epilepsy do not respond adequately to an-
tiepileptic drugs (AEDs) [1]. Epilepsy is deﬁned as refractory when un-
controlled seizures continue after two or more appropriate AED
treatments [2].r nucleus of thalamus; AUDIT,
pression Inventory; DBS, deep
epression Rating Scale; MRI,
entory; SCL-90, The Symptom
of thalamus for epilepsy, trial;
y and Rehabilitation, Tampere
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. This is an open access article underDeep brain stimulation (DBS) is a promising therapy for epilepsy. The
bilateral anterior nucleus of thalamus (ANT) DBS has been studied previ-
ously [3–7]; in a double-blind randomized controlled trial, it was reported
to reduce the frequency of seizures in patients with refractory epilepsy
[8]. Since 2010, it has been CE (Conformité Européenne)-approved for
epilepsy therapy in Europe, and it recently received approval from the
Food and Drug Administration (FDA) in the USA. There is only limited
knowledge of the basic mechanisms of DBS or of the optimal stimulation
parameters. It has been suggested thatDBSdisrupts or inhibits epileptiform
activity in epileptogenic thalamocortical networks [9].
The thalamus is connected and functionally related with the cortex
and limbic structures. The ANT has a role in seizure activity in both ab-
sence and focal seizures; moreover, it is a part of the hippocampal sys-
tem for episodic memory and has connections with the anterior
cingulate and orbitomedial prefrontal cortex. Through its connections,
it may contribute to both emotional and executive functions [10,11].
The ANT stimulation has been reported to activate the cingulate gyrus,
insular cortex, and lateral neocortical temporal structures [12], whichthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
374 S. Järvenpää et al. / Epilepsy & Behavior 88 (2018) 373–379all have projections to amygdala, a structure involved in the initiation of
emotional responses [13].
There is a bidirectional association between epilepsy anddepression,
and there could be some common pathophysiological mechanisms un-
derlying the onset of epilepsy and psychiatric disorders including de-
pression and anxiety [14,15]. Therefore, ANT DBS might impact
psychiatric signs and symptoms. There are a few reports of psychiatric
adverse effects related to ANT stimulation. In the stimulation of the an-
terior nucleus of thalamus for epilepsy, trial (SANTE) study [8], the pa-
tients in the active stimulation group reported more depressive
symptoms compared with the control group (sham). One depression
event in the active stimulation group was serious (suicide). Some, but
not all patients, who experienced depression had also a prior history
of depression. Subjective reports of depression and memory impair-
ments have also been reported [16].
The aim of the present study was to evaluate previous or present
psychiatric symptoms in patients intending to undergo an ANT DBS op-
eration and to evaluate if these can predict possible psychiatric adverse
effects that they might experience after the operation. The types of psy-
chiatric adverse effects and also their management are described and
also reported here.
2. Materials and methods
Twenty-two patients (14 males and 8 females; 36± 11.5 years old)
with bilateral ANT DBS for refractory epilepsy participated in this study.
The age of onset of epilepsy was 14± 8.6 years. The patients were se-
verely ill; the mean frequency of their seizures was 42/month. The
groupwas heterogenic with respect to epilepsy type, age of onset, med-
ications, and burden of disease.
The patients had their ongoing AED treatments, and the possible
psychiatric medications were also continued at the time of operation.
All patients gave written informed consent. The study protocol was
approved by Tampere University Hospital Ethics Committee.
TheDBS deviceswere implanted by a neurosurgeon in TampereUni-
versity Hospital during February 2010 to March 2016. The DBS elec-
trodes (3389, Medtronic, Inc.) were implanted under general
anesthesia using a Leksell Stereotactic Frame (Elekta). The initial stereo-
tactic target was 5–6 mm lateral, 0–2 mmanterior, and 12mmsuperior
respective to themidcommissural point (MCP). The target was then ad-
justed according to each individual's anatomy in the 3-Tmagnetic reso-
nance imaging (MRI) (Siemens) short tau inversion recovery (STIR)
images by visualizing the mammillothalamic tract.
When the operation was being planned, a psychiatric interviewwas
performed at baseline by an experienced psychiatrist concentrating on
former and current psychiatric symptoms and medications. The fol-
low-up visit was conducted at one year after the surgery. The Symptom
Checklist-90 [17] (SCL-90) was performed to evaluate the subjective
psychiatric symptoms. Beck Depression Inventory [18] (BDI) andMont-
gomery and Åsberg Depression Rating Scale [19] (MADRS)were used to
assess the presence and severity of depressive symptoms. The Alcohol
Use Disorders Identiﬁcation Test (AUDIT) [20] was used to evaluate
the risks associated with alcohol use. Neuropsychiatric symptoms
were inquired by using the Neuropsychiatric Inventory [21] (NPI). In-
crease in score indicates increased severity in symptoms in all of the
tests used.
The stimulation was initiated using the optimal contacts with a
voltage of 5 V, 90 μs pulse width, and 140 Hz frequency. The cycling
was 1 min on and 5 min off. The contacts or parameters were
changed according to clinical judgment to improve the stimulation
response in relieving epileptic seizures or due to psychiatric adverse
effects.
Three-dimensional (3D)models of DBS electrodes, ANT, and volume
of activated tissue were constructed with Medtronic SureTune II
software using preoperative 3-Tesla MRI and postoperative computer
tomography (CT) scan fusion images.3. Results
There was no signiﬁcant psychiatric morbidity in the whole study
group. At baseline, the mean BDI score was 6.3 (range: 0–19), and
MADRS was 2.7 (range: 0–8) in 18 patients (missing data in four pa-
tients). After one year, the corresponding values were BDI: 7.8 (range:
0–24, 20 patients, missing data in two patients) and MADRS: 5.1
(range: 0–11, 18 patients, missing data in four patients). Five patients
were being prescribed with psychiatric medication before the opera-
tion: antidepressants, antipsychotics, and diazepam (DZP). Clobazam
(CLB) and clonazepam (CLN) were used for epileptic seizures. One pa-
tient had a history of severe transient psychotic episodes of aggression
and paranoid delusions and mental confusion one year before the DBS
operation but did not experience DBS-related psychiatric adverse ef-
fects later. Some AED changes were made during the follow-up
(Tables 1 & 2), but these did not cause the improvement in seizure con-
trol or mood changes in any of our patients.
Two patients experienced sudden-onset depressive andmelancholic
symptoms that were associated with programming. These symptoms
appeared within a few days after adjusting the initial stimulation pa-
rameters; these were managed by either reducing the stimulation cur-
rent or changing the contacts. In one of the patients (patient 2, Fig. 2),
this took place at 1 month after the operation, and in the other patient,
at 1.5 years after the implantation (patient 4, Fig. 4). Moreover, other
kinds of psychiatric symptoms were detected in two patients; these in-
cluded irritation, sleep disturbances, anxiety, fear, and paranoid symp-
toms. These symptoms developed slowly, over months, and were
successfully managed also by adjusting the stimulation parameters
and changing the active contacts (Figs. 1 & 3). The patients with these
adverse effects and their management are described below (four case
examples). Both patients with depressive adverse effects had former
histories of depression, but none of them had previously experienced
paranoid or anxiety symptoms.
3.1. Patient 1 (Fig. 1)
Awoman in her late 40s had experienced focal epilepsy since 33 years.
She was working as an assistant, and she lived alone. Her epilepsy was re-
fractory despite several AED trials. Her seizure frequency ranged from14 to
34/month. This patient was not a candidate for resective surgery. Vagus
nerve stimulation (VNS) had been tried without any response. She had
no former psychiatric history. Levetiracetam (LEV) had induced some de-
pressive thoughts that vanished after discontinuation of the medication.
Immediately after ANT DBS, she felt more active but was not diagnosed
as being hypomanic. Monopolar stimulation was initiated with active con-
tacts 2/10 (voltage: 4/4 V, therapeutic current: 4/6.6 mA current, 90 μs
pulse width, and 140 Hz frequency). After six months, her seizure fre-
quency was halved. Unfortunately, after 10months of stimulation, the pa-
tient reported sleep disturbances and feeling depressive, and soon
afterwards, she began to feel paranoid and annoyed. The changewas insid-
ious andhappenedwithout any clear triggering factors. Her initial psychiat-
ric symptoms were mild but worsened gradually to an outright psychotic
state including delusions and erotomanic thoughts. There were no signs
of delirium, and the patient remained conscious and oriented throughout.
She also began to experience psychogenic nonepileptic seizures along
with anxiety and low mood. The patient had experienced similar
nonepileptic seizures 8 years before, and these were conﬁrmed at that
timebyvideo-electroencephalography (VEEG)aspsychogenicnonepileptic
seizures. Citalopram (CIT) 20mgwas provided to treat her depression and
anxiety. The stimulation contacts were also changed tomore cranial, active
contactsweremoved to3 and11, and the currentwasdecreased to5.9mA/
6.3mA (right/left). After this reprogramming, the patient felt better, and
gradually, her psychotic symptomsdisappeared. Citalopramwas continued
40mg/day, patient also had her ongoing AEDs: zonisamide (ZNS) 400mg,
pregabalin (PGB) 600mg, and lacosamide (LCM) 400mg, quetiapine 25
mg was administered in the evening for sleep disturbances, when
Table 1
Responders (n=15).Age, yearswithepilepsy, andmedicationaredeﬁnedat the timeof implantation.OnlyAEDsandpsychiatricmedicationaredetailed. Responder status isdeﬁnedbyat least a50%
seizure reduction in the dominant seizure type at 1 year after the surgery [22]. The case histories of the patients 1–3 are described in more detail in the text.
Abbreviations: CBZ, carbamazepine; CD, cortical dysplasia; CIT, citalopram; CLB, clobazam; CLN, clonazepam; DZP, diazepam; ESL, eslicarbazepine acetate; LCM, lacosamide; LEV, levetiracetam; LTG,
lamotrigine; MZP, mirtazapine; NA, not available; OXC, oxcarbazepine; PGB, pregabalin; PHT, phenytoin; PSY, psychiatric; RIS, risperidone; TPR, topiramate; VPA, valproic acid; ZNS, zonisamide.
Patient Sex Age Years with
epilepsy
AED/PSY medication (mg)
baseline→ at 1 year
BDI baseline→
at 1 year
MARDS baseline→
at 1 year
Etiology Epileptic zone
1 F 48 33 ESL 1600→ 0, LCM 0→ 400, PGB 600, ZNS 400 0→ 0 2→ 5 Unknown Left occipital
2 F 24 7 CLB 20, CIT 20, OXC 1500, TPR 400 7→ 12 3→ 5 Encephalitis Multifocal
3 M 29 9 CBZ 100, CLB 10→ 20, MZP 0→ 30 0→ 2 0→ 5 CD Multifocal
5 F 32 31 CLN 8→ 6, PHT 200 1→ 3 4→ 9 CD Left frontal
6 M 30 18 CBZ 1200, CLB 30, CIT 10→ 15 NA→ 13 NA CD Multifocal
7 F 26 19 OXC 1500→ 1800, CLB 15, ZNS 400→ 300 NA→ 4 NA→ 0 CD Multifocal
8 F 36 10 CBZ 800, CIT 40→ 30, DZP 0→ 20, KTP 0→ 600,
LCM 200, LEV 1000, RIS 2→ 1, ZNS 400
5→ 0 1→ 0 CD Right frontal
9 M 23 14 CLB 20, LTG 150, VPA 1500, ZNS 400 14→ 11 4→ 2 Encephalitis Multifocal
10 F 31 3 CLB 20, LCM 0→ 500, OXC 1000, ZNS 500→ 200 16→ 16 6→ 8 Encephalitis Multifocal
11 M 47 38 CBZ 400, CLB 15, ZNS 400 1→ 7 1→ 4 Unknown Frontal
12 M 49 44 CBZ 600, LCM 400 4→ 7 2→ 9 Encephalitis Right temporal
13 M 40 32 CLB 20→ 25, OXC 1650, ZNS 400 NA NA CD Multifocal
14 M 56 42 OXC 1800 0→ NA 0→ NA Unknown Multifocal
15 M 29 20 OXC 1800, VPA 1300, ZNS 200 19→ 0 1→ 0 Unknown Right frontal
16 M 22 7 LCM 200, OXC 900, ZNS 500 7→ 9 4→ 10 Encephalitis Left hemisphere
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(a 90% reduction compared with pre-DBS baseline). Her mood stabilized,
and the psychotic symptoms had relieved when evaluated in the one-
year follow-up.
3.2. Patient 2 (Fig. 2)
A woman in her mid-20s had refractory epilepsy after presumed en-
cephalitis since 8 years. She lived alone and worked part-time as an assis-
tant. Her seizures had failed to improve with multiple AED trials, and she
was not a candidate for resective surgery. Vagus nerve stimulation was
tried without any meaningful response. Epileptic seizures (biparietal sei-
zure onset zone) occurred 14 to 32 times/month. She had had depressive
symptoms and antidepressant medication after the onset of epilepsy but
not before that time. She was receiving long-standing and still ongoing
CIT 20-mg medication at the time of ANT DBS operation. At the baseline
psychiatric evaluation, no depressive symptoms were present.
Stimulation was induced with active contacts 2/10 (voltage: 5/5 V,
90 μs pulse width, and 140 Hz frequency). Voltage was gradually in-
creased to 6.5 V,which inducedmelancholia, tiredness, sadness, and so-
matic complaints which appeared within two days. The effect was seen
in BDI, she had a score of 33 points i.e., evidence of severe depression.
This depressive effect vanished (BDI: 9) when the voltage was de-
creased to 5 V, again within two days. With these parameters, there
was no change in her seizure frequency. When the contacts were
changed to 3, 10, and 11 with the same parameters, the seizure fre-
quency was further decreased. Furthermore, changing the contacts to
3 and 11, 5/4 V, the response to the stimulation in seizure frequency
was even better, a 61% reduction.Table 2
Nonresponders (n= 7). Age, years with epilepsy, and medication are deﬁned at the time of im
by at least a 50% seizure reduction in the dominant seizure type at 1 year after the surgery [22]. O
year, however, reaching responding status later with optimal stimulation parameters. The case
Abbreviations: CIT, citalopram; CLB, clobazam; ESL, eslicarbazepine acetate; LCM, lacosamid
topiramate; VPA, valproic acid; ZNS, zonisamide.
Patient Sex Age Years with epilepsy AED/PSY medication (mg)
baseline→ at 1 year
BDI ba
year
4* F 54 35 LCM 500→ 600, TPR 400→ 300 7→ 13
17 M 22 10 VPA 2500 NA
18 M 48 37 CLB 20→ 40, LCM 400, OXC 1500 0→ 1
19 M 24 5 CLB 30, LEV 2000, OXC 1800, TPR 600 18→ 2
20 M 45 9 CIT 20, LCM 400, LEV 3000, OXC 1200 5→ 11
21 M 50 49 CLB 10, LCM 400, PAM 8 2→ 4
22 F 31 8 ESL 2000, LEV 3000, ZNS 400 7→ NAA similar emergence of melancholia, sadness, crying, and depressive
thoughts was seen three times when the current or pulse width in any
of the chosen contacts was increased; and these were managed by de-
creasing the voltage and ultimately, by changing the contacts more cra-
nial to 3 and 11. The AEDs used were oxcarbazepine (OXC) 1500 mg,
topiramate (TPR) 400 mg, and CLB 20 mg. Citalopram 20 mg was also
continued.
3.3. Patient 3 (Fig. 3)
Aman in his late 20s had refractory temporal lobe epilepsy due to bi-
lateral subependymal heterotopia since 10 years. The patient was not a
candidate for resective surgery. Epilepsy was refractory; seizures in the
patient had failed to improvewithmultiple AED trials, and epilepsy sur-
gery was also considered. Postictal neuropsychiatric symptoms of ag-
gression and confusion had been present, but the patient had no
former or present psychiatric symptoms at the time of the ANT DBS op-
eration. Stimulation was initiated with active contacts 2/10 (voltage:
2.5/2.5 V, 90 μs pulsewidth, and 140 Hz frequency). The voltage was in-
creased gradually to 6.5 V. One year after the operation, the patient
started to complain about low mood, but both BDI and MADRS scores
indicated a euthymicmood (2 and 5, respectively). In the SCL-90 assess-
ment, obsessions and depression were evident, and the patient also felt
anguished. He reported fear, irritation, andmemory problems. Intermit-
tent periods with paranoid thoughts were also present. Mirtazapine
(MZP) 30 mg and risperidone (RIS) 1 mgwere started, which improved
the situation. Contacts 3 and 11 were added. The current was 10mA on
each side. The seizure frequency was improved by 80% as compared
with baseline, but the patient still had paranoid thoughts, somaticplantation. Only AEDs and psychiatric medication are detailed. Responder status is deﬁned
ne patient ismarkedwith an asterisk; that patientwas still a nonresponder during theﬁrst
history of patient 4 is described in more detail in the text.
e; LEV, levetiracetam; NA, not available; OXC, oxcarbazepine; PAM, perampanel; TPR,
seline→ at 1 MARDS baseline→ at 1
year
Etiology Epileptic zone
5→ 9 Hippocampal sclerosis + CD Left temporal
NA Encephalitis Multifocal
2→ 2 CD Right temporal
4 8→ NA Unknown Left parietal
2→ 8 Unknown Right frontal
0→ 0 Ischemic lesion Right frontal
3→ NA Encephalitis Multifocal
Fig. 1. Patient 1. The stimulationwas initiatedwith contacts 2 and10. Gradually, the patient started to experience a change inmood andhad feelings of beingmonitored and eavesdropped.
Bizarre thoughts i.e., feeling that she was magnetic started to appear (a). The stimulated contacts were changed to being more cranial to 3 and 11 and her psychotic symptoms started to
dissipate (b).
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chiatric medications. His psychiatric symptomswere gradually worsen-
ing, and patient had become more paranoid with aggressive thoughts.
The active contacts were changed to 3 and 11, voltage was 6.5/6.5 V,
and pulse width was 90 μs with a frequency of 140 Hz, which resulted
in a reduction in his psychiatric symptoms. In this case, the slowly initi-
ating, alternating, and gradually worsening irritation, anxiety, and para-
noid thoughts were seen as adverse effects to the stimulation. His
symptoms became reduced when more cranial contacts were chosen,
and the current was decreased. This patient was rather similar with
case 1. He was prescribed with carbamazepine (CBZ) 100 mg and CLB
10mg as AEDs.
3.4. Patient 4 (Fig. 4)
This patientwas similar to case 2. Awoman in hermid-50s had tem-
poral lobe epilepsy due to hippocampal sclerosis and cortical dysplasia
since 34 years. She was also diagnosed with rheumatoid arthritis. She
had had no former psychiatric symptoms. Temporal resection and
amygdalohippocampectomia was conducted at the age of 45 years.
After epilepsy surgery, she was initially seizure-free for other seizure
types except auras. The following AEDs were used: CBZ 1050 mg and
TPR 200 mg. Five years after her surgery, seizures with impaired aware-
ness (FIAS) reappeared with increasing frequencies. Simultaneously,
the patient felt depressive, and CIT 20 mg was started from which she
beneﬁted. Five years later, ANT DBS was chosen to treat the patient's
temporal lobe epilepsy. In the preoperative psychiatric interview, the
patient had no depressive symptoms, BDI: 7, MADRS: 5. She felt tense
after the surgery and was afraid of the seizures, and this induced some
anxiety in the patient. Stimulation was initiated with bipolar settings,
contacts 2 and 10 were positive, and 3 and 11 were negative (voltage:
3.5/4 V, 90 μs pulse width, and 140 Hz frequency). The current was
gradually increased to 6 mA, and after 6 months, the seizure frequency
was decreased by 75% compared with baseline. Theminimal depressive
symptoms and the fear of seizures had become alleviated; CIT was
discontinued. Nonetheless, her seizure frequency was not optimal.
Stimulation was changed to being monopolar, active contacts were 3and 11, voltage 4.5/5 V, other parameters were not changed. With
these settings, the patient experienced again sudden depressive
thoughts, butwhen the currentwas decreased to 7 mA bilateral, her de-
pression vanished. Rating scalewas not collectedduring sudden depres-
sive thoughts. The total seizure frequency was improved by 32% when
compared with baseline.4. Discussion
At the group level, no signiﬁcant changes on mood were observed
after ANT DBS treatment in our study. Two patients experienced abrupt
depressive symptoms related to the DBS programming settings; these
were quickly alleviated by decreasing the intensity of the stimulation
butwithout changing the active contacts. In addition, two patients grad-
ually experienced paranoid and anxiety symptoms which again im-
proved slowly after changing the programming settings from contacts
inferior to ANT to ones inside ANT.
In linewith previous studies [8,23], there were no severe psychiatric
adverse effects in these 22 patients who underwent ANT DBS for refrac-
tory epilepsy. Moreover, the four moderate psychiatric adverse effects
could be clinicallymanaged by reprogramming the stimulator in collab-
oration with specialists. Previously, depression has been reported to
worsen in some patients who had had a previous depressive history
[23,24], however, it has not been previously reported that there can be
a sudden appearance and disappearance of depression with these ﬂuc-
tuations being dependent on the stimulation parameters. It is true that
the present patients with depressive adverse effects had previously ex-
perienced depression, and therefore, it may be considered as a predis-
posing factor. Paranoid and anxious reactions occurred after the
stimulation, a phenomenon that has also not been demonstrated before.
This reaction scenario appears to be related to the stimulation of deep
structures beneath the ANT, and it has a gradual onset. It is important
to recognize these symptoms and react early since severe depressive
and paranoid symptoms may endanger the success of the whole treat-
ment. On the other hand, the described symptomswere transient in na-
ture and reversible after changes to the stimulation parameters.
Fig. 2. Patient 2. (a) Contacts 3/10/11 were activated for stimulation, which resulted in an
increase in the current from 5.8 mA on the left and 5.9 on the right to 6.1 mA on the left
and 9.3 mA on the right. The patient developed depressive symptoms. (b) The voltage
was switched to 5 V on the left and 4 V on the right. This resulted in a decrease in the
current and a disappearance of depressive symptoms. (c) Voltage was raised from
bilateral 5 V to bilateral 6.5 V, which led to the appearance of new depressive
symptoms. (d) Adjusting the voltage back to bilateral 5 V eliminated the depressive
symptoms. (e) Pulse width was increased from 150 μs to 180 μs again inducing
depressive symptoms. (f) Reducing the pulse width back to 150 μs eliminated the
depressive symptoms.
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with regard to etiology, seizure burden, medication, and level of cogni-
tive abilities.When evaluatingmood and cognitive functions before and
after DBS, there are several confounding factors that need to be consid-
ered. The psychiatric evaluation is challenging in this patient group al-
though BDI and MADRS can be used to assess depressive symptoms
and their severity. By using the SCL-90, the psychiatric symptoms can
also be detected, but very often, patients with epilepsy are fearful
about their seizures and are susceptible to self-observation, and these
symptoms can be falsely interpreted as anxiety. The beneﬁt of SCL-90
is the possibility to compare the symptoms at different time points.
The burden of disease is also a fact that should be considered.
Mood disorders and cognitive decline are common comorbidities of
epilepsy, and thus, the effects of DBS on psychiatric and neuropsycho-
logical states have attracted increasing interest. According to the current
evidence, signiﬁcant stimulation-related and persistent psychiatric
symptoms are infrequent in ANT DBS patients [25–27]. In our sample,
when these symptoms did emerge, they were reversible with reduction
in stimulation. Mild reductions did not impede seizure control. In a ran-
domized controlled trial, a subjective deterioration ofmood andmemory
was reported during a blinded phase [8]. In the long-term follow-up,
most neuropsychological test results improved [8,23,24]. The majority
of patients with self-reported and objectively assessed depression had
preexisting depression [24]. This was also the case in our two patients
with depressive adverse effects. One study reported a deteriorated re-
sponse inhibition and improved attention allocation towards a threat in
ANTDBS patients [28]. It has been claimed that ANTDBSmight exert pos-
itive effects on mood [8,24], verbal ﬂuency, and delayed verbal memory
[29] at 1–2 years after surgery, though the concurrent seizure reduction
means that the interpretation of these results is susceptible to confound-
ing. A voltage-dependent sleep disruption caused by ANT DBS has been
reported; this may be related to subjective symptoms of cognition and
mood [30]. Psychotic and depressive symptoms have been suggested to
be associatedwith dramatic reduction of seizure frequency— a phenom-
enon referred to as forced normalization [31].
These patients were carefully evaluated before the surgery, and the
clinical evaluation and management of possible psychiatric adverse ef-
fects were conducted in close collaborationwith a neurosurgeon, a neu-
rologist, and a psychiatrist. The adverse effects described here were all
managed by changing the stimulation parameters. There seemed to be
a pattern of the sudden appearance of a depressive effect in response
to a high current, and theremay be caudal contacts that were also man-
aged rapidly by adjusting the parameters. At the group level, a history of
psychiatric symptomsdid not seem to predispose to psychiatric adverse
effects of ANT DBS, although two patients with depressive adverse ef-
fects had previous histories of depression. Moreover, the feelings of
paranoia and anxiety were more slowly appearing and harder to detect
psychiatric adverse effects; they were also managed with
reprogramming, but the recovery was slower. Although, even these ad-
verse effects were clinically managed, in a worst-case scenario, they
couldwell jeopardize the success of DBS treatment. The sudden appear-
ance of severe depression may lead to serious consequences. Moreover,
the patient with paranoid thoughts insisted that the device should be
removed. In addition, the compliance with psychiatric medications
and treatments can be poor in these occasions. Moreover, when the ir-
ritable feelings, anxiety, and paranoid thoughts are transient and ﬂuctu-
ating, they might be hard to detect during clinical outpatient
appointments or settings. Therefore, the close collaboration between
psychiatrists, neurologists, and neurosurgeons is crucial.
Overall, the majority of our ANT DBS patients did not experience
psychiatric adverse effects. Although, certain DBS parameters might
predispose to the sudden appearance of depressive or slowly manifest-
ing paranoid symptoms, thesewere found to be reversible via program-
ming changes. If left untreated, these symptomsmight compromise the
ANT DBS treatment. Because of self-reported depression and memory
problems and the crucial positioning of the ANT within the Circuit of
Fig. 3. Patient 3. (a) Initially stimulated with contacts 2 and 10, deeper contacts 1 and 9 were also activated for stimulation. The patient started to feel anxious soon after the change.
Psychiatric symptoms were relieved by initiation of RIS therapy. The patient contacted doctors and nurses frequently with overly long incoherent messages; he started to experience
psychotic symptoms and repeatedly refused reprogramming of DBS contacts. Three years after the initiation of stimulation with deep contacts, the patient was nervous and tense at
the follow-up appointment and was found in the clinic's bathroom in a confused state. (b) Finally, the patient consented to changing the stimulated contacts to the uppermost 3 and
11. After this change, the psychotic symptoms became gradually relieved.
378 S. Järvenpää et al. / Epilepsy & Behavior 88 (2018) 373–379Papez, a reputed regulator of mood and memory, it is recommended
that a neuropsychological and psychiatric evaluation of ANT DBS
patients should be done routinely prior to and after the surgery.
The current evidence on psychiatric adverse effects has been mostly
limited to studies with small sample sizes and confounding factors.Fig. 4. Patient 4. The current increased from 6.8 mA to 9mA on the left and from 6.6 mA to 8.3 m
(a) to monopolar stimulation of 3 and 11 (b). The patient started experiencing depressive sym
voltage on the right remained at 4.5 V. This lowered the currents to 7.1 mA on the left and 7.4
seizure frequency.More studies with reliable designs, standardized neuropsychological
and psychiatric assessment protocols, and larger sample sizes will be
needed to investigate the independent effects of ANT DBS and the
signiﬁcance of particular stimulation parameters on mood and
cognition.Awhen transitioning from bipolar stimulation of anodes 2 and 10 and cathodes 3 and 11
ptoms, which were relieved by lowering the voltage on the left from 4 V to 3.5 V while
mA on the right and resulted in relief of her depressive symptoms and a decrease in the
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